Connect Biopharma Holdings Limited (CNTB): Price and Financial Metrics

Connect Biopharma Holdings Limited (CNTB): $1.28

-0.01 (-0.78%)

POWR Rating

Component Grades













Add CNTB to Watchlist
Sign Up

Industry: Biotech



in industry

CNTB Stock Price Chart Interactive Chart >

Price chart for CNTB

CNTB Price/Volume Stats

Current price $1.28 52-week high $5.10
Prev. close $1.29 52-week low $0.56
Day low $1.22 Volume 54,300
Day high $1.30 Avg. volume 59,050
50-day MA $0.85 Dividend yield N/A
200-day MA $1.09 Market Cap 70.50M

Connect Biopharma Holdings Limited (CNTB) Company Bio

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

CNTB Latest News Stream

Event/Time News Detail
Loading, please wait...

CNTB Latest Social Stream

Loading social stream, please wait...

View Full CNTB Social Stream

Latest CNTB News From Around the Web

Below are the latest news stories about CONNECT BIOPHARMA HOLDINGS LTD that investors may wish to consider to help them evaluate CNTB as an investment opportunity.

Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | January 16, 2023

Connect Biopharma Provides Business and Clinical Development Program Update

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program Progress of China pivotal AD trial remains on track with completion of 36-week Stage 2 expected in H2 2023 SAN DIEGO and TAICANG, SUZHOU, China, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq:

Yahoo | December 30, 2022

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma will present a corporate update on January 9, at 9:00 am PST, during the upcoming Biotech Showcase taking place in person January 9 – 11, 2023. Conn

Yahoo | December 19, 2022

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that, on November 28, 2022, it received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) indicating that, for the last 30 consecutive business days, the bid price fo

Yahoo | December 2, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time for another dive into the biggest pre-market stock movers as we check out the latest stock news for Thursday morning!

William White on InvestorPlace | October 27, 2022

Read More 'CNTB' Stories Here

CNTB Price Returns

1-mo 72.27%
3-mo 46.65%
6-mo 57.02%
1-year -68.86%
3-year N/A
5-year N/A
YTD 47.50%
2022 -83.15%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5932 seconds.